CELLAVISION AB (publ) - Interim report for the period January 1 - March 31, 2009

Continued strong sales trend during the first quarter of 2009

*    Net sales for the quarter rose by 19% to SEK 22.0 million
  (18.5).
*    The operating profit for the period was SEK 0.9 million (1.3).
*    Earnings per share for the period amounted to SEK 0.02 (0.05).
*    Cash and cash equivalents amounted to SEK 14.5 million (16.1) by
  the end of the quarter.
*    CellaVision qualified for trade on NASDAQ OMX First North
  Premier on February 16, 2009.

Important events after the reporting period
*    The Japanese subsidiary received its first order.
*    David Autry was appointed President of CellaVision North
  America.
*    CellaVision was nominated for the SwedenBIO Award for its
  successes during 2008.



  CellaVision in summary
   (MSEK)          Jan-March Jan-March Full year
                     2009      2008      2008
  Net sales             22.0      18.5     100.4
  Gross profit          14.1      11.9      63.5
  Operating result       0.9       1.3      13.4
  Net result             0.5       1.2      13.1
  Cash flow             -5.2      -0.3       3.3



CEO's comment"The first quarter indicates a continued strong sales growth, and  we
are still dedicated  to our aim  of furthering growth  and profit  in
2009," says  Yvonne  Mårtensson, CEO  of  CellaVision. "As  yet,  the
financial crisis has not translated  into a loss of orders;  however,
the purchasing processes tend to take longer for hospital  customers.
North America  accounted  for  the  majority  of  sales  during  this
quarter, and Dave Autry has now been appointed President of our North
American operations.""It is  also  satisfying  to  report  that  our  Japanese  subsidiary
received its first  order in  April from the  hospital laboratory  in
Tokyo that  has  been  evaluating  the product  for  some  time.  The
laboratory at Tokyo Medical Center is a good reference to have in our
future penetration of the important Japanese market.""Our  growth  is  also   owing  to  technological  development.   The
development of a new hardware  platform has reached an intense  phase
of prototype assembling and testing.  This has resulted in  increased
costs, which in turn  has an effect on  results despite the fact  the
SEK 4.8 million was capitalized  as expenditure for development.  The
main parts of these costs are now  taken. A new product based on  the
new hardware platform  will be launched  in the second  half of  this
year."

Yvonne Mårtensson
CEO CellaVision AB


For more information please contact:
Yvonne Mårtensson, CEO. Tel: +46 708 33 77 82, e-mail:
yvonne.martensson@cellavision.com
Johan Wennerholm, CFO. Tel: +46 708 33 81 68, e-mail:
johan.wennerholm@cellavision.com


Download the report by pressing the link below.